Aquestive Therapeutics, Inc. AQST Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Co-development and research fees | $1.28M-33.6% | $1.93M+37.3% | $1.4M+8.4% | $1.29M-20.9% | |
| License and royalty revenue a | $3.52M-77.1% | $15.35M+185% | $5.38M+129% | $2.35M-65.0% | |
| Manufacture and supply revenue | $40.23M+0.6% | $39.98M-8.7% | $43.81M+20.4% | $36.38M+3.0% | |
| Proprietary product revenue, net | -$478K-252% | $315K— | —— | —— | |
| Total Selling expenses by Product | |||||
| Other | $14.77M+186% | $5.16M+566% | $775K— | —— | |
| Personnel costs | $3.72M+56.1% | $2.38M+176% | $864K— | —— | |
| Total General and Administrative Expenses by Product | |||||
| Other | $41.53M+92.5% | $21.57M+11.5% | $19.34M— | —— | |
| Personnel costs | $19.83M-5.9% | $21.06M+95.6% | $10.77M— | —— | |
| R&D by Product | |||||
| Anaphylm project expenses | $5.82M-38.6% | $9.47M+62.6% | $5.83M— | —— | |
| AQST-108 project expenses | $497K-36.8% | $786K— | $0— | —— | |
| Other | $2.23M-2.9% | $2.3M+18.8% | $1.93M— | —— | |
| Personnel costs | $8.65M+12.0% | $7.72M+24.0% | $6.23M— | —— | |
| Revenue by Geography | |||||
| Ex-United States | $14.94M-15.3% | $17.63M+30.8% | $13.48M+95.7% | $6.89M-13.6% | |
| United States | $29.6M-25.9% | $39.93M+7.6% | $37.1M-9.0% | $40.79M-4.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aquestive Therapeutics, Inc. break its business down?
- Aquestive Therapeutics, Inc. (AQST) reports revenue by product across 4 parts — Co-development and research fees, License and royalty revenue a, Manufacture and supply revenue and Proprietary product revenue, net. Each is extracted from the segment footnotes and tracked over time.
- Where does Aquestive Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aquestive Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
